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Background: Cancers escape immune surveillance via distinct mechanisms that involve central (negative selection within the
thymus) or peripheral (lack of costimulation, receipt of death/anergic signals by tumor, immunoregulatory cell populations)
immune tolerance. During the 1990s, moderate clinical benefit was seen using several cytokine therapies for a limited number
of cancers. Over the past 20 years, extensive research has been performed to understand the role of various components of
peripheral immune tolerance, with the co-inhibitory immune checkpoint molecules cytotoxic T-lymphocyte antigen 4 (CTLA-
4), programmed death 1 (PD-1), and its ligand (PD-L1) being the most well-characterized at preclinical and clinical levels.
Patients and methods: We used PubMed and Google Scholar searches to identify key articles published reporting
preclinical and clinical studies investigating CTLA-4 and PD-1/PD-L1, frequently cited review articles, and clinical studies of
CTLA-4 and PD-1/PD-L1 pathway inhibitors, including combination therapy strategies. We also searched recent oncology con-
gress presentations and clinicaltrials.gov to cover the most up-to-date clinical trial data and ongoing clinical trials of immune
checkpoint inhibitor (ICI) combinations.
Results: Inhibiting CTLA-4 and PD-1 using monoclonal antibody therapies administered as single agents has been associated
with clinical benefit in distinct patient subgroups across several malignancies. Concurrent blockade of CTLA-4 and compo-
nents of the PD-1/PD-L1 system using various schedules has shown synergy and even higher incidence of durable antitumor
responses at the expense of increased rates of immune-mediated adverse events, which can be life-threatening, but are rarely
fatal and are reversible in most cases using established treatment guidelines.
Conclusions: Dual immune checkpoint blockade has demonstrated promising clinical benefit in numerous solid tumor types.
This example of concurrent modulation of multiple components of the immune system is currently being investigated in
other cancers using various immunomodulatory strategies.
Key words: immuno-oncology, cytotoxic T-lymphocyte antigen 4, programmed death 1, peripheral immune tolerance, im-
mune exhaustion, cancer
Introduction
Established cancers developwhen they escape immune system regu-
lation [1] and evolve into one of two cancer types. Inflamed cancers
are usually immunogenic and rich in innate immune signals,
chemokines for recruitment of T cells and other immune cell sub-
sets, as well as tumor infiltration by various immune cell subsets
[2]. Conversely, noninflamed cancers are often the end-product of
poorly immunogenic transformed cells that have evolved when the
host immune system has already eradicated highly immunogenic
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transformed cell clones. In noninflamed cancers, there are low or
absent chemokine expression, lack of T-cell infiltration, potentially
higher numbers of immunoregulatory populations (naturally
occurring T-regulatory cells [Treg], myeloid-derived suppressor
cells), and denser stroma. Noninflamed cancers comprise the ma-
jority of cancers, which, in part, explains the relatively low response
rates seen with immunotherapies.
More recently, various mechanisms by which tumors escape
immunosurveillance have been identified [3]. These mechanisms
are usually induced by tumor cells themselves and/or the micro-
environment, although primary or iatrogenic immunosuppression
or inefficient activation of effector T cells may have a role (Figure 1
and supplementary Table S1, available at Annals of Oncology on-
line). The lack of T cell effector function may be no different from
other types of chronic inflammation, such as that seen in infec-
tions. More specifically, chronically stimulated effector T cells pro-
gressively lose effector function and eventually die. During this
progressive decline, typically called exhaustion, immune check-
point proteins (ICP) play important and dynamic roles. Immune
cell death by exhaustion may account for the possibility that some
cancers may be immunogenic, although low or absent immune cell
infiltration within the tumor is observed [4].
Four issues are critical with respect to T-cell exhaustion in can-
cer. First, multiple ICPs can be simultaneously expressed
[5]. Second, not all ICPs contribute equally to immune cell func-
tion and/or dysfunction. Among several co-inhibitory im-
mune checkpoint systems, the CTLA-4/CD80/CD86 and PD-1/
PD-L1/PD-L2 pathways have clinically significant roles in periph-
eral immune tolerance [6]. Third, the net effect on T-cell function
is the sum of all co-stimulatory and co-inhibitorymolecules simul-
taneously expressed in T cells. Fourth, T-cell exhaustion often co-
exists with other immunoregulatory mechanisms within the
tumor (Figure 1) [7]. This may explain why single-agent immuno-
therapies have demonstrated variable efficacy across cancer types
and why a combination approach, using agents targeting disease-
specificmechanisms of immunosuppression, can be synergistic.
Various immunotherapies targeting distinct aspects of the im-
mune system are either approved for clinical use or
in development. This review provides an overview of novel
single-agent and combination strategies that target the im-
mune system. We will focus on the combination of CTLA-4 and
PD-1 immune checkpoint inhibitors (ICIs), which has recently
been approved in the USA for advanced melanoma and is cur-
rently being tested in other tumor types. We describe the ration-
ale for this approach, the clinical data to date, and strategies for
managing patients receiving combination ICP blockade.
Materials and methods
We used PubMed and Google Scholar searches to identify key articles pub-
lished since 2004 reporting preclinical and clinical studies
investigating CTLA-4 and PD-1/PD-L1, frequently cited review articles
about ICPs and the immune system, and clinical studies of CTLA-4 and
PD-1/PD-L1 pathway inhibitors, including combination therapy strategies.
We also included recent congress presentations from international oncol-
ogy meetings to cover the most up-to-date clinical trial data and searched
the clinicaltrials.gov database to identify ongoing clinical trials of ICI
combinations.
Peripheral immune tolerance: focus on the
CTLA-4/CD80/CD86 and PD-1/PD-L1/PD-L2
pathways
ICPs are essential for maintaining peripheral self-tolerance during
physiologic conditions. Different ICPs operate at various stages,
anatomic locations, and impact distinct cell subsets of immune sys-
tem activation (supplementary Table S2, available at Annals of
Oncology online) [5].Most co-inhibitory ICPs, such as CTLA-4 and
PD-1, are upregulated in response to T-cell receptor activation as a
physiologic response against unnecessary or prolonged immune
system activation that may potentially damage normal tissues.
CTLA-4 is upregulated early in this process and may induce T-cell
inhibition by outcompeting with the costimulatory molecule CD28
for its ligands [8]. CTLA-4 is also required for the suppressive ac-
tions of Treg cells in secondary lymphoid organs or other peripheral
tissues, including tumor sites [9]. Conversely, PD-1 is highly ex-
pressed on activated T cells after prolonged T-cell receptor stimula-
tion [4]. Similar to CTLA-4, PD-1 is also required for their
suppressive functions and for development of peripherally induced
Treg cells [10, 11]. Therefore, treatment with CTLA-4 inhibitors ex-
pands the number of T-cell clones that recognize a broader number
of tumor antigens [12], whereas treatment with PD-1 inhibitors
preferentially increases the number of preexisting T-cell clones that
recognize distinct tumor antigens [13, 14]. The ligands for PD-1,
PD-L1 and PD-L2, are physiologically expressed by other immune
cells as well as nonimmune cells. However, induction of PD-L1 ex-
pression can also be seen in peripheral tissues [8]. In malignancy,
the expression of PD-L1 on cancer cells appears to be regulated in a
complex set of interactions in part mediated by inflammatory cyto-
kines. Preclinical melanoma models demonstrate an increase in
PD-L1 expression in response to IFN-c and suggest that this is
driven by the presence of CD8þT cells as part of a negative feedback
loop [7, 15]. More recent work further highlights the underlying
complexity in this system, suggesting specific genetic alterations in
the GTPase RAC1 have the ability to modulate PD-L1 expression in
melanoma cells [16]. Conversely, it is possible to have induction of
PD-L1 that is independent from the presence of tumor-infiltrating
lymphocytes (TILs) [17–22]. This observation is clinically relevant
because PD-L1-positive, TIL-negative cancers may define a cancer
type thatmay not be responsive to immunotherapies [23].
In summary, CTLA-4 and PD-1/PD-L1 exhibit distinct roles in
regulating immune system activation. CTLA-4 limits T-cell acti-
vation and clonal expansion, and the PD-1/PD-L1/PD-L2 path-
way limits T-cell function in the peripheral tissues, although the
extent to which the PD-1 pathway is involved in early T cell pri-
ming in addition to modulation of effector function remains to
be fully characterized. These spatiotemporal differences in the
role of CTLA-4 and PD-1 provide the basis for combined block-
ade of CTLA-4 and PD-1 to increase effector T-cell response, dis-
cussed in further detail below.
Clinical development of inhibitors of CTLA-4
and the PD-1/PD-L1 pathway as single
agents in cancers
Table 1 shows key clinical trials testing monoclonal antibodies
targeting various ICPs [14, 24–54]. Ipilimumab, a monoclonal
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antibody against CTLA-4, was approved in the USA in 2011 for
the treatment of patients with unresectable or metastatic melan-
oma on the basis of improved overall survival (OS) in two
randomized, controlled phase III trials [24, 55]. In a recent
pooled analysis of data from 10 prospective and 2 retrospective
studies, including 2 phase III trials, ipilimumab demonstrated
long-term OS in 20% of patients with advanced melanoma
[56]. Although toxicities can be life-threatening, most serious ad-
verse events (AEs) were reversible and treatable in clinical studies
using established management algorithms [24, 55]. High-dose
ipilimumab (10 mg/kg) has demonstrated increased recurrence-
free survival (RFS) of 9 months versus placebo when adminis-
tered in the adjuvant setting in patients at high risk for relapsing
stage III melanoma, although the impact on OS is not yet known
[57]. Based on the improvement in RFS, ipilimumab was recently
approved by the FDA for this indication. In a randomized phase
III trial in metastatic melanoma, tremelimumab, another mono-
clonal antibody to CTLA-4, was compared against physician’s
choice chemotherapy, but failed tomeet its primary OS endpoint.
Post hoc analysis suggested that a considerable number of patients
who were randomized to the control arm received standard-of-
care ipilimumab following progression, potentially confounding
the OS difference between these two groups [25].
Nivolumab and pembrolizumab, two monoclonal antibodies
against PD-1, were both approved in 2014 for the treatment of
patients with unresectable stage III or distant metastatic melan-
oma and disease progression following ipilimumab and, if har-
boring a BRAFV600 mutation, a BRAF inhibitor [14, 58]. The
indications for each agent were subsequently expanded to
first-line therapy based on results from two separate studies:
nivolumab demonstrated an improvement in OS compared with
dacarbazine in patients with previously untreated metastatic mel-
anoma without a BRAFV600 mutation [27] and pembrolizumab
(at 10 mg/kg every 2 or 3 weeks) showed improved OS when
compared to ipilimumab in advanced melanoma patients who
had received at most one prior therapy [33]. Based on collective
data supporting improved clinical efficacy, as well as reduced
rates of toxicity, compared to ipilimumab, PD-1 therapy is estab-
lished as an option for first-line therapy in patients with advanced
melanoma [59]. Additionally, the indications for PD-1/PD-L1
based therapy continue to expand across many tumor types.
Patients with advanced, previously treated squamous non-small
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Figure 1. Mechanisms of immune tolerance. Immune tolerance involves a range of overlapping mechanisms that involve not only the periphery (e.g. tumor site), but also central lymphoid
organs, especially thymus. They include intrathymic negative regulation (central), decreased costimulation, anergic signals from tumor cells, and immunoregulation (e.g. from Treg and MDSC
[peripheral]). Arg1, arginase 1; HLA, human leukocyte antigen; ICP, immune checkpoint protein; IDO, indoleamine 2,3-dioxygenase; IGF-1, insulin-like growth factor; IL-10, interleukin 10; KGF,
keratinocyte growth factor; MDSC, myeloid-derived suppressor cell; MHC, major histocompatibility complex; NF-jB, nuclear factor kappa-B; PD-L1, programmed death ligand 1; STAT, signal
transducer and activator of transcription; RANKL, receptor activator of nuclear factor kappa-B ligand; TGF, transforming growth factor; Treg, regulatory T cells; VEGF, vascular endothelial growth
factor.
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cell lung cancer (NSCLC) who received nivolumab had a 41%
lower risk of death compared to standard chemotherapy in a
randomized phase III trial [28]. Similarly, the hazard ratio for
death in patients with metastatic renal cell carcinoma who
received nivolumab was 0.73 compared with everolimus in a
randomized phase III trial [29] and was 0.70 compared with in-
vestigator’s choice in patients with squamous cell carcinoma of
the head and neck [31]. Early investigation of pembrolizumab in
NSCLC and of atezolizumab, a PD-L1 blocking antibody, in
advanced urothelial cancer showed high antitumor responses in
patients bearing tumors that express high levels of PD-L1 [37,
60]. In addition, pembrolizumab treatment in patients with squa-
mous cell carcinoma of the head and neck resulted in an 18% and
25% ORR in HPV-positive and -negative patients, respectively
[35]. Certain aspects of the tumor microenvironment have been
associated with favorable immunotherapy responses, such as mu-
tational burden [61–63] and virally driven cancers [64–66], offer-
ing insights to the spectrum of activity of co-inhibitory ICPs
across more cancers.
Treatment combinations of peripheral ICIs
and other strategies
Rationale for combinations other than inhibitors of
CTLA-4 and PD-1
There are several barriers that limit responses to immunothera-
pies and to peripheral immune checkpoint inhibition, in particu-
lar. First, constitutive activation of several signaling pathways,
such as theWnt or the PI3K/Akt pathway, prevents influx of TILs
[67, 68]. Second, several tumors may have low somatic mutation
burden, which has been associated with resistance to immune
checkpoint therapies, although this interaction is not completely
understood as it is still possible to derive benefit from immuno-
therapy with a lowmutational burden [63]. External beam irradi-
ation has been studied in the context of a combination strategy,
and while there are substantial preclinical data to suggest that ra-
diation therapymay synergize with immune checkpoint blockade
via various mechanisms, at this point the clinical data are more
limited [13, 69]. Third, absolute lymphocyte counts are fre-
quently low in patients with metastatic cancers, which is a result
of spontaneous or tumor-cell-induced death [70]. This can occa-
sionally be restored using immunotherapies that promote sur-
vival signals for T-cell growth and proliferation, such as high-
dose bolus interleukin 2, a T-cell growth factor. Fourth, central
(thymic) tolerance, a critical process to prevent autoimmunity,
can restrict antitumor responses and limit the generation of
tumor antigen-specific effector T cells [71]. Fifth, even within
inflamed tumors there are variable degrees of both immunosup-
pression and peripheral immune tolerance. For example, tumor
antigen-specific CD8þ cells that express high levels of two co-
inhibitory ICP are more exhausted compared with those that ex-
press only one ICP [72], and T cell Ig ad ITIM domain is upregu-
lated on tumor antigen-specific CD8þ cells and CD8þ tumor-
infiltrating lymphocytes from patients with melanoma [73]. In
addition, tumors may simultaneously contain various immunor-
egulatory cell types (Treg, myeloid-derived suppressor cells) and/
or express high levels of enzymes that breakdown essential amino
acids for T-cell growth (indoleamine 2,3-dioxygenase [IDO],
arginase), in addition to high levels of ICP. In fact, there is now
preclinical and early clinical evidence that targeting the PD-1/
PD-L1 pathway in combination with IDO inhibition may be syn-
ergistic [74, 75]. Supplementary Table S3 and Table 2, available at
Annals of Oncology online, show preclinical and clinical evidence,
respectively, for combining peripheral ICI with other immuno-
therapies or treatment modalities [76–82].
Rationale for CTLA-4 and PD-1 combination
CTLA-4 andPD-1/PD-L1 have complementary and synergistic roles
in regulating activation via the T-cell receptor [83]. Blockade of
CTLA-4 prevents the induction of tolerance and increases the num-
ber and repertoire of activated T cells [8, 12, 84]. PD-1 blockade
restimulates previously primed T cells that have lost effector and
proliferative function during the course of an immune response [4,
5, 12]. Concurrent PD-1 and CTLA-4 blockade restores ability of
tumor-infiltrating CD8þ cells to produce IL-2 and therefore stimu-
lates T cell growth, whichmay inhibit Treg-mediated suppression of
antitumor responses [10, 13, 75, 85, 86]. Simultaneous blockade of
both CTLA-4 and PD-1 should, therefore, increase the number of T
cells participating in an antitumor response and prolong antitumor
response by preventing PD-1:PD-L1-mediated downregulation and
suppression by Tregs (Figure 2) [17, 87]. A recent study that tested
the effects of anti-PD-1 or anti-CTLA-4 alone or in combination in
patients’ blood and tumor tissue has shown that each treatment in-
duces distinct immunologic effects and no overlapping changes in
gene expression [88].
Clinical approaches and efficacy with CTLA-
4 and PD-1 blockade
Efficacy of immune-checkpoint combinations
Based on the efficacy seen in preclinical studies, trials using com-
binations of anti-CTLA-4 and anti-PD-1 have been conducted in
patients with melanoma and other cancers.
Phase I trial. A phase I trial evaluated ipilimumab plus nivolu-
mab (IþN) in patients with unresectable stage III or IV melan-
oma [89]. Patients (n¼ 53) received escalating doses of
concurrent nivolumab and ipilimumab for four cycles, followed
by nivolumab monotherapy for four cycles. The regimen that
consisted of nivolumab 1mg/kg plus ipilimumab 3mg/kg was se-
lected for further investigation in phase II and III trials in meta-
static melanoma. Across all concurrent cohorts, the objective
response rate (ORR) was 40%, including early (i.e. within
12 weeks) and deep (i.e.80% tumor shrinkage) responses that
were unrelated to BRAFV600 mutation status. A recent long-term
follow-up demonstrated 1-, 2-, and 3-year OS rates of 85%, 79%,
and 68%, respectively [90]. The data from this study are encour-
aging and represent a dramatic shift from historical OS rates.
Phase II trial. A phase II randomized double-blind study showed
significantly improved efficacy with combination IþN versus ipi-
limumab alone (Table 3) [91, 92]. Treatment-naı¨ve patients with
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Table 2. Selected clinical trials testing the combination of peripheral ICI with other therapies
Combination therapy Study design Cancer, stage Study phase and
trial number
Vaccines
gp100, MART-1, and NY-ESO-1þ
nivolumab [76]
Vaccinesþnivolumab 1, 3, or 10mg/kg, Q2W12 Melanoma, IIIC Phase I, NCT01176461
GM-CSF
Ipilimumabþsargramostim [77] Ipilimumab 10mg/kg (day 1)þsargramostim 250lg
(day 1–14)
Melanoma, III/IV Phase II, NCT01134614
Interferon
Ipilimumabþpeginterferon alfa-
2b [78]
Ipilimumab 3 or 10mg/kg, Q3W12þpeginterferon
alfa-2b
Melanoma, III/IV Phase II, NCT01496807
VEGF
Ipilimumabþbevacizumab [79] Ipilimumab 3 or 10mg/kgþbevacizumab
7.5 or 15mg/kg Q3W
Melanoma, III/IV Phase I, NCT00790010
Small-molecule inhibitors
Atezolizumabþvemurafenib or
Atezolizumabþvemurafenibþ
cobimetinib
Atezolizumab 15–20mg/kg Q3W, 800mg Q2W or
1200mg Q3W
Melanoma, III/IV Phase Ib, NCT01656642
Atezolizumabþcobimetinib Fixed doses of both or MPD fixed
doseþcobimetinib escalating doses
Solid tumors, metastatic Phase I, NCT01988896
Pembrolizumabþdabrafenibþ
trametinib
Pembrolizumab (days 1, 22)þdabrafenib 150mg/kg
BID (day 1)þtrametinib 2mg QD (day 1)
Melanoma, III/IV Phase I/II, NCT02130466
Dabrafenibþipilimumabþtra-
metinib [80]
Dabrafenib 100 or 150mg BIDþipilimumab 3mg/kg
Q3W
Dabrafenib 100 or 150mg BID (2 weeks) þtrameti-
nib 1 or 2mg QDþipilimumab 3mg/kg Q3W
Melanoma, III/IV Phase I, NCT01767454
Durvalumabþtrameti-
nib6dabrafenib [81]
Durvalumab 3 or 10mg/kg Q2Wþdabrafenib
150mg BIDþtrametinib 2mg QD or trametinib
alone
Melanoma, III/IV Phase I/II, NCT02027961
IDO inhibitors
Pembrolizumabþepacadostat
(INCB024360)
Pembrolizumab 2mg/kg Q3Wþepacadostat 25mg
BID
Solid tumors, metastatic
melanoma
[64]
Ipilimumabþepacadostat Ipilimumab 3mg/kg Q3Wþepacadostat 25mg,
50mg, 75mg BID
Melanoma, metastatic or
unresectable
Phase I/II, NCT01604889
Ipilimumabþindoximod Ipilimumab 3mg/kg Q3Wþindoximod 600mg BID Melanoma, metastatic Phase I/II, NCT02073123
Oncolytic virus
PembrolizumabþT-VEC Pembrolizumab Q2W (Ib) Q3W (III)þ
T-VEC intralesional Q2W (Ib) wk 0, 3, 5, 7 then
Q3W
Melanoma, III/IV Phase Ib/III, NCT02263508
Chemotherapy
Pembrolizumabþchemotherapy
(gemcitabine, docetaxel, nab-
paclitaxel, vinorelbine, irinote-
can, doxorubicin)
Pembrolizumab 2mg/kgþgemcitabine 1000mg/
m2 (days 1, 8) Q3W
Pembrolizumab 2mg/kgþgemcitabine 900mg/
m2þdocetaxel 75mg/m2 (day 8) Q3W
Pembrolizumab 2mg/kgþgemcitabine 1000mg/
m2þnab-paclitaxel 125mg/m2 (days 1, 8) Q3W
Pembrolizumab 2mg/kgþgemcitabine 1000mg/
m2þvinorelbine 25mg/m2 (days 1, 8) Q3W
Pembrolizumab 2mg/kgþirinotecan 300mg/m2
(day 1) Q3W
Pembrolizumab 2mg/kgþdoxorubicin 30mg/m2
(day 1) Q3W
Breast cancer, sarcoma,
pancreatic cancer, SCLC,
metastatic
Phase I/II, NCT02331251
Pembrolizumabþchemotherapy
(paclitaxel, carboplatin, bevaci-
zumab,
pemetrexed, erlotinib, gefitinib)
or immunotherapy (ipilimumab)
Pembrolizumab 2 or 10mg/kgþpaclitaxel 200mg/
m2þcarboplatin 6mg/ml/min (day 1) Q3W
Pembrolizumab 2 or 10mg/kgþpaclitaxel 200mg/
m2þcarboplatin 6mg/ml/minþ
bevacizumab 15mg/kg (day 1) Q3W
NSCLC Phase I/II, NCT02039674
Continued
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metastatic melanoma (n¼ 142) were randomized 2:1 to receive
ipilimumab (3 mg/kg every 3 weeks [Q3W]) concurrently admin-
istered with either nivolumab (1 mg/kg Q3W) or placebo for four
doses, followed by nivolumab (3 mg/kg) or placebo every 2 weeks
(Q2W) until disease progression [91, 92]. Overall, ORR was sig-
nificantly higher with IþN compared with ipilimumab mono-
therapy (59% versus 11%) [91]. At a minimum follow-up of
24.5 months, patients who received the combination had pro-
longed PFS compared with patients who received
ipilimumab alone, and the 2-year OS rate for all randomized pa-
tients was 64% for the combination and 54% compared with ipili-
mumab monotherapy; median OS had not been reached in either
group (hazard ratio 0.74, 95% CI 0.43–1.26; P¼ 0.26) [92]. In the
combination group, ORR was independent of tumor PD-L1 status
(58% for PD-L1-positive and 55% for PD-L1-negative tumors). In
the ipilimumab monotherapy group, a numerically higher ORR
was observed among patients with PD-L1-positive compared with
PD-L1-negative tumors (18% versus 4%). The results from this
trial led to accelerated approval of the combination in the USA
based on tumor response rate and durability of response.
Phase III trial. In the first phase III trial to evaluate the role of
concurrent versus single-agent immune checkpoint blockade for
the treatment of patients with metastatic melanoma (Table 3)
[91–100], 945 treatment-naı¨ve patients were randomized 1:1:1 to
receive IþN at the phase II schedule or single-agent nivolumab
3 mg/kg Q2W plus placebo, versus single-agent ipilimumab
Q3W plus placebo, until disease progression or unacceptable tox-
icity [93]. At a median follow-up of 12 months, both the IþN
and nivolumab monotherapy groups demonstrated improved
PFS and higher investigator-assessed ORR compared with ipili-
mumab alone, a benefit that was observed across predefined sub-
groups [101]. At a median follow-up of 20.7 months, OS data
were too immature to analyze [102].
Although PFS for the combination was more prolonged com-
pared with nivolumab alone (11.5 months versus 6.9 months, re-
spectively), the study was not statistically powered to formally
assess this difference. In patients whose tumors had at least 5%
PD-L1 expression using the PD-L1 IHC 28-8 pharmDx immuno-
histochemical assay [103], PFS with the IþN combination was
numerically higher compared with nivolumab monotherapy
(11.2 months versus 5.3 months, respectively). Subset analysis
in relation to PD-L1 expression suggests that patients bearing
PD-L1-positive tumors who received the combination did not
have significantly longer PFS compared with single-agent nivolu-
mab. Accordingly, at this time PD-L1 should not be used for
Table 2 Continued
Combination therapy Study design Cancer, stage Study phase and
trial number
Pembrolizumab 2 or 10mg/kgþpemetrexed
500mg/m2þcarboplatin 5mg/ml/min (day 1)
Q3W
Pembrolizumab 2mg/kgþipilimumab 0.3, 1, or
3mg/kg (day 1) Q3W
Pembrolizumab 2mg/kg (day 1) Q3Wþerlotinib
150mg QD
Pembrolizumab 2mg/kg (day 1) Q3Wþgefitinib
250mg QD
Carboplatin 5mg/ml/minþpemetrexed 500mg/
m26pembrolizumab 200mg (day 1) Q3W
Nivolumab6gemcitabine/cis-
platin, pemetrexed/cisplatin, car-
boplatin/paclitaxel, bevacizu-
mab maintenance, erlotinib or
ipilimumab
Various doses and schedules NSCLC Phase I, NCT01454102
Nivolumabþchemotherapy
(temsirolimus, irinotecan,
irinotecanþcapecitabine)
Nivolumab 3mg/kgþtemsirolimus 25mg Q2W
Nivolumab 3mg/kgþirinotecan 150mg/m2 Q2W
Nivolumab 3mg/kgþirinotecan 175mg/m2 (day 1)
Q2Wþcapecitabine 1000mg BID (days 1–5) QW
Pancreatic cancer,
RCC, NSCLC, CRC
Phase I/II, NCT02423954
Atezolizumabþ
bevacizumab6FOLFOX [82]
Atezolizumab 20mg/kg Q3Wþbevacizumab
15mg/kg Q3W
Atezolizumab 14mg/kg Q2Wþbevacizumab
10mg/kg Q2WþmFOLFOX6 at standard doses
CRC Phase I, NCT01633970
Radiation therapy
Chemoradiation with or without
sequential durvalumab
NSCLC Phase III, NCT02125461
BID, twice daily; CRC, colorectal cancer; GM-CSF, granulocyte-macrophage colony-stimulating factor; ICI, immune checkpoint inhibitors; IDO, indole-
amine 2,3-dioxygenase; MPD, myeloproliferative disease; NSCLC, nonsmall cell lung cancer; Q2/3W, every 2/3 weeks; QD, everyday; RCC, renal cell car-
cinoma; SCLC, small cell lung cancer; T-VEC, talimogene laherparepvec; VEGF, vascular endothelial growth factor.
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clinical management andmaking decisions between combination
and single-agent anti-PD-1 therapy, based solely on these results.
Safety profile with dual CTLA-4 and PD-1 inhibition
ICI are associated with immune-related AEs that typically affect
skin, gastrointestinal, hepatic, endocrine, pulmonary, and renal
organ systems. Table 4 lists grade 3/4 treatment-related AEs re-
ported in trials combining CTLA-4 and PD-1 inhibitors.
Although the spectrum of AEs with IþN was similar to mono-
therapy, the incidence of serious (grade 3 or 4) AEs was higher in
the IþN arm compared with monotherapy-treated patients
(69% versus 44% and 56%, respectively) [91, 93, 104, 105].
Additionally, there is a suggestion that irAEs may occur early in
the course of therapy with combination treatment, potentially
after only one cycle [106, 107]. The safety profile across all phases
was consistent, and treatment-related AEs were generally well-
managed and resolved with established safety guidelines
(supplementary Tables S4 and S5, available at Annals of Oncology
online) [91, 93, 104]. Notably, although four deaths related to
combination therapy were reported across the phase I and II
studies, no treatment-related deaths were reported in the multi-
center phase III trial (109 institutions, 21 countries) among pa-
tients receiving the combination regimen [91, 93, 104]. Towards
identifying a concurrent IþN regimen with comparable efficacy
but a better safety profile, different schedules that decrease fre-
quency and dose of ipilimumab in melanoma and NSCLC may
preserve efficacy but definitely reduce life-threatening adverse
events [95, 101]. Of note, a recent analysis of 35 patients who dis-
continued IþN on the phase II study due to toxicity demon-
strated a similar response rate (66%) to the overall study
population (59%), with the potential for durable benefit [108],
suggesting that continued observation may be a reasonable op-
tion for this patient cohort.
Clinical insights for managing patients receiving
ICIs
Supplementary Table S5, available at Annals of Oncology online,
provides an overview of immune-related AE management strat-
egies, which emphasizes differential diagnoses, use of steroids,
and a multidisciplinary approach. If a patient has a moderate to
severe AE that is potentially immune-mediated, treatment should
be delayed or discontinued. Steroids are typically used to reduce
immune reactions [14, 91, 93]. In some instances, immune
checkpoint therapy can be resumed following resolution of an
AE; however, patients experiencing a severe AE should perman-
ently discontinue therapy. In patients presenting with acute fa-
tigue, weight loss, diarrhea, nausea, emesis, or arthralgia, a
workup for endocrinopathies (in particular, hypophysitis)
should be done. Prompt hormone replacement therapy amelior-
ates symptoms of endocrinopathies and may allow continued
therapy with ICI in some cases [109].
As yet, there is insufficient evidence about whether the efficacy
of IþN is adversely affected by corticosteroids. To date, pooled
data from studies testing single-agent nivolumab or ipilimumab
suggest that use of immune modulators to manage immune-
related AEs does not significantly alter the efficacy to any of these
agents [26, 110, 111].
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
has been studied in combination with ipilimumab. In a randomized
multicenter study, ipilimumab (10 mg/kg) plus GM-CSF improved
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Figure 2. Implications of CTLA-4 and PD-1 dual pathway blockade. Interruption of CTLA-4:B7 binding by T cells in lymph nodes via anti-CTLA-4 increases T-cell proliferation, activation,
and survival, potentially leading to an increased number of activated T-cell clones that can respond to tumor antigens. Blockade of PD-1:PD-L1 binding at the tumor site via anti-PD-1 restores
the activity of antitumor T cells that have become inactivated. CTLA-4 and PD-1 blockade may also reduce the suppressive effects of Tregs at the tumor site. Please note that T cells may ex-
press other (i.e. non-CTLA-4, non-PD-1, PD-L1) co-stimulatory (þ?) as well as co-inhibitory immune checkpoint proteins (-?), whereas tumor cells upregulate almost exclusively co-inhibitory
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OS, though not PFS, and showed lower rates of serious AEs com-
pared with ipilimumab alone [77]. The implications of reduced tox-
icity with combination treatment versus monotherapy may be
worth exploring oncemore data are available.
Patient selection
From a safety standpoint, most studies have been conducted in
patients with normal hepatic and renal function, although there
are no absolute contraindications to therapy with ICI.
Additionally, patients with a history of autoimmune disease
(AID) have been excluded from clinical trials based on concerns
of increased risk of developing immune-related AEs and possible
diminished clinical benefit if patients are actively treated with sys-
temic immune modulators [112–114]. It is the authors’ practice
to consider therapy on an individual basis for patients with AID,
after careful discussion of the risks and benefits, as clinical re-
sponses can be seen [115].
Development of biomarkers to assist in patient selection for
therapy with ICI has trailed that of other therapies, such as small-
molecule inhibitors. This may have significant economic impli-
cations due to the high cost of these agents over prolonged
treatment periods [116]. This is especially likely if they are to
be given in combination, either in cancers with low response
rates to PD-1/PD-L1 pathway inhibitor studies; or even in can-
cers with high response rates (e.g. melanoma) but adminis-
tered during earlier stages of cancer (e.g. adjuvant).
Immunohistochemical expression of PD-L1 in tumor tissues
seems to be the most promising biomarker so far and is cur-
rently used as an FDA-approved companion diagnostic test in
patients with NSCLC who are considered for treatment with
pembrolizumab [60]. Other tumor tissue-based tests that
assess PD-L1 are likely to be FDA-approved as companion
diagnostics in combination with other PD-L1 inhibitors [117].
Initial evidence suggested that patients with PD-L1-express-
ing tumors may have higher response rates and longer PFS to
PD-1/PD-L1 pathway inhibitors than patients treated with
anti-PD-1 monotherapy with low or negative PD-L1 expres-
sion [33, 118–120]. However, PD-L1 was not a predictive bio-
marker in phase III randomized trials in RCC and squamous
cell NSCLC [121]. Moreover, patients with PD-L1 negative
tumors still benefit from treatment with these agents when
compared with other treatments [120]. This may be attributed
to the fact that expression of PD-L1 is heterogeneous with re-
spect to stage (primary versus metastatic), metastatic organs
involved, and prior systemic or local treatment effects [122].
Screening for PD-L1 expression by immunohistochemistry,
however, may be important in patients who would otherwise
be considered for IþN as opposed to single-agent nivolumab,
as the margin for PFS benefit to the combination therapy was
greatest in patients with PD-L1-negative metastatic melanoma
[93]. In the future, PD-L1 expression could factor into the
complex decision-making involved with individualized patient
treatment, however it has not yet been validated for this pur-
pose at this time.
Analysis of pretreatment tumor tissues from patients who went
on to receive pembrolizumab showed that preexisting high num-
bers of TILs in the vicinity of PD-L1- and PD-1-expressing cells
had the greatest tumor response from pembrolizumab in meta-
static melanoma [123]. ImmunoscoreTM is already a commer-
cially available test (HalioDx) that accurately quantifies the
density and distribution of TILs using standardized immunohis-
tochemistry and computer imaging algorithms in formalin-fixed,
paraffin-embedded tumor tissues with prognostic and predictive
implications for therapy [124, 125]. It may likely assist in classify-
ing cancers based on the tumor microenvironment and to facili-
tate prediction of response to ICI and other immuno-oncology
agents [23, 126, 127]. Possibly, a combined tumor tissue bio-
marker that considers both immunoscore and PD-L1 expression
is important [23], especially for patients who are considered for
IþN therapy. Other predictive methodologies also continue to
be investigated. Recently, multiparameter flow cytometry for
PD-1 and CTLA-4 on freshly isolated mononuclear cells from
tumor tissues was found to be a predictor of response to PD-1
monotherapy in metastatic melanoma [128]. Functionally, this
T-cell subset demonstrated a partially exhausted phenotype.
Interestingly, in a separate cohort of 24 patients treated with
IþN, increased levels of PD-1 high/CTLA-4 high T cells were
not predictive of benefit [129]. While it remains a critical ques-
tion, the optimal biomarker to guide patient selection has yet to
be defined.
Ongoing immune checkpoint combination studies
in patients with advanced malignancies
Within melanoma the concurrent IþN regimen is FDA-
approved for unresectable stage III or IV disease and is being eval-
uated in patients with active brain metastases (NCT02374242).
Early data on the IþN regimen in other solid tumors suggest
that combination treatment may have higher response rates com-
pared with single-agent nivolumab on most occasions (Table 3).
Table 4. Rates of grade 3/4 treatment-related AEs reported in trials of con-
current CTLA-4 and PD-1 pathway blockade [91, 93, 104, 105]
Grade 3/4 AEs (%)
All treatment-related AEs 51–64
Colitis 4–17
Lipase increased 9–15
ALT increased 8–12
AST increased 6–11
Diarrhea 7–11
Rash 5–9
Amylase increased 6
Pyrexia 0–3
Fatigue 1–5
Dyspnea 3
Hypophysitis 2
Pneumonitis 2
Headache 2
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate ami-
notransferase; CTLA-4, cytotoxic T-lymphocyte antigen 4; PD-1, pro-
grammed death-1.
Review Annals of Oncology
70 | Salama and Moschos Volume 28 | Issue 1 | 2017
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/article-abstract/28/1/57/2676861 by U
niversity of N
orth C
arolina at C
hapel H
ill user on 13 August 2019
Ongoing studies are investigating other combinations of CTLA-4
and PD-1/PD-L1 pathway inhibitors in other tumor types (Table
3). The anti-PD-L1 agent durvalumab is also being combined
with an anti-PD-1 agent (MEDI0680; AMP 514) in the first trial
to target both the PD-1 receptor and its key ligand on the basis of
preclinical data showing synergy [130]. This combination is
being evaluated in patients with advanced malignancies, includ-
ing melanoma (NCT02118337) (Table 3).
The success and promise of CTLA-4 and PD-1/PD-L1 pathway
inhibitors has paved the way to investigate the therapeutic poten-
tial of other antibodies that target co-inhibitory or co-
stimulatory ICP (Table 3). The list of prospective drug targets is
large, and clinical trials testing antibodies against CD137, LAG-3,
CD200, and KIR have offered early results of safety and activity.
Clinical trials testing drugs against several other ICPs were re-
cently opened to accrual or are ready to enroll patients (e.g. OX-
40, CD40, CD27, Tim-3, GITR). Although the number of permu-
tations for simultaneous targeting of these proteins is daunting,
the most promising combinations will be ultimately defined by
the cancer type-specific biology and in vivo testing in appropriate
cancer-specific animal models.
Conclusion
The field of immuno-oncology is expanding rapidly, with the po-
tential for broad application across multiple tumor types. ICIs are
changing the treatment expectations for cancer patients, offering
durable and deep responses for many patients. Combinations of
immuno-oncology agents have shown improved response rates
compared with single-agent therapy, although the high rate of
grade 3/4 AEs remains a potential concern. This emphasizes the
need for vigilance in AE identification, prompt management using
established guidelines, appropriate risk stratification, and the need
for better biomarkers of response that may rely on tumor biology
and agent’s MOA (PD-L1 negative, immunoscore low/absent).
Ongoing studies seek to refine patient selection and identify novel
combination approaches, which may lead to safer andmore effect-
ive treatments.
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